DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference
DICE Therapeutics, a biopharmaceutical company focused on immunology, will present at the Jefferies Healthcare Conference on June 9, 2022, at 2:30 p.m. ET. This presentation will highlight their innovative approach using proprietary technology to develop oral therapeutics for chronic diseases. Key therapeutic targets include IL-17, α4ß7 integrin, and αVß1/αVß6 integrin. A live and archived webcast of the presentation can be found on their website, available for 90 days post-event.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:30 p.m. ET.
A live and archived webcast of the presentation can be accessed under “Events & Presentations” on the Investors section of the Company's website. The archived webcast will be available on the Company’s website for 90 days after the event.
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Contact:
Katie Engleman, 1AB
katie@1abmedia.com
FAQ
What date will DICE present at the Jefferies Healthcare Conference?
What time is DICE's presentation scheduled for during the Jefferies Healthcare Conference?
Where can I watch the DICE Therapeutics presentation?
How long will the DICE Therapeutics webcast be available?
What are the therapeutic targets being developed by DICE Therapeutics?
